Document is current
Any future updates will be listed below
-
Authors
Dona, Ada Alice
Tandoh, Theophilus
Nigam, Lokesh
Singer, Mahmoud
Caserta, Enrico
Murtadha, Mariam
Zhu, Yinghui
Moloudizargari, Milad
Sharma, Preeti
Napolitano, Ottavio
Winchester, Janet
Chowdhury, Arnab
Pozhitkov, Alex
Sanchez, James F.
Vahed, Hawa
Marcucci, Guido
Coffey, Matt
Nuovo, Gerard
Sborov, Douglas W.
Pichiorri, Flavia
Hofmeister, Craig C
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA194742)
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 26 November 2024
First Online: 20 January 2025
Declarations
:
: The Ohio State University Cancer Institutional Review Board (Columbus, OH) approved this study, and informed consent was obtained from all enrolled patients (, NCT 02101944). All animal experiments were approved by the City of Hope Institutional Animal Care and Use Committee.
: Not applicable.
: GJN received research funding from Oncolytics Biotech Inc. MC is employed by Oncolytics Biotech Inc. CCH received research funding from BMS, Oncolytics Biotech, Sanofi, and Nektar; he received personal funds from GlaxoSmithKline, Oncopeptides, BMS, Janssen, Sanofi, and Celgene for advisory board participation, and patent-related funds from Recursion Pharmaceuticals. DWS received personal funds for consultation and advisory board participation from Sanofi, Janssen, SkylineDx, GlaxoSmithKline, Legend Biotech and Amgen.
